Aurobindo Pharma’s arm gets 11 observations from USFDA for Telangana Formulation facility

07 Feb 2026 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities’ Unit-III has been inspected by the United States Food and Drug Administration (USFDA). The inspection was conducted from January 27 to February 06, 2026 and concluded with 11 observations. The observations are procedural in nature. The Unit-III is a Formulation manufacturing facility of Eugia Pharma Specialities situated in Telangana. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1279.30 -12.10 (-0.94%)
23-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1756.35
Dr. Reddys Lab 1252.55
Cipla 1222.70
Zydus Lifesciences 860.55
Lupin 2297.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×